ClinicalTrials.gg
CompletedNCT07597928Updated Oct 1, 2026

A Study to Learn How Different Forms of the Study Medicine Called PF-08049820 Are Absorbed and Eliminated in Healthy Adults

A Phase 1 interventional study of PF-08049820 and Rabeprazole in Healthy Adults and Healthy, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Updated Oct 1, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to learn how different forms of the study medicine called PF-08049820 are absorbed and eliminated in healthy adults. The study will assess whether the study medicine is absorbed differently when taken with or without food. It will also assess absorption when the study medicine is taken with another medicine called rabeprazole. Rabeprazole is an FDA approved medicine that reduces stomach acid.

The study has two parts. In Part A, participants will take three forms of study medicine, one after the other. They will take each form either with or without food for a total of five doses. Each dose will be separated by a few days. Participants will stay in the clinic for about two weeks. They will receive a telephone follow-up call about a month after the last dose.

In Part B, participants will take three forms of study medicine. They will take each one with or without food, and with or without another medicine called rabeprazole. This means they will take a total of six doses of study medicine. Each dose will be separated by a few days. Participants will stay at the clinic for about three weeks, and about a month after their last dose. They will get a follow-up phone call. Part B may or may not be conducted depending on the results from Part A.

The study is seeking participants who:

  1. Are males or females,
  2. Are at least 18 years of age,
  3. Have a body mass index (BMI) 16 to 32 kilograms per meter squared (kg/m2). Have a total body weight of more than 50 kilograms (kg) (110 pounds).
02

Conditions studied

  • Healthy Adults
  • Healthy
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males and females.
  2. At least 18 years of age
  3. (BMI) of 16-32 kg/m2; and a total body weight >50kg (110 lb.).

Exclusion criteria

Exclusion Criteria:

  1. Evidence or history of medical conditions.
  2. History of (HIV) infection, , or ; positive testing for HIV, hepatitis B or hepatitis C.
  3. History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening.
  4. Participation in studies of other products (drug or vaccine) at any time during their participation in this study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Sequence 5 (Part A)

    3 different formulations of PF-08049820 administered orally under fasted or fed conditions.

    Drug: PF-08049820

  • Experimental
    Sequence 7 (Optional Part B)

    3 different formulations of PF-08049820 administered orally with or without rabeprazole under fasted or fed conditions.

    Drug: PF-08049820 · Drug: Rabeprazole

  • Experimental
    Sequence 1 (Part A)

    3 different formulations of PF-08049820 administered orally under fasted or fed conditions.

    Drug: PF-08049820

  • Experimental
    Sequence 2 (Part A)

    3 different formulations of PF-08049820 administered orally under fasted or fed conditions.

    Drug: PF-08049820

  • Experimental
    Sequence 3 (Part A)

    3 different formulations of PF-08049820 administered orally under fasted or fed conditions.

    Drug: PF-08049820

  • Experimental
    Sequence 4 (Part A)

    3 different formulations of PF-08049820 administered orally under fasted or fed conditions.

    Drug: PF-08049820

  • Experimental
    Sequence 6 (Part A)

    3 different formulations of PF-08049820 administered orally under fasted or fed conditions.

    Drug: PF-08049820

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)

    Part A: Evaluate the relative bioavailability of different formulations of PF-08049820. Optional Part B: Estimate the effect of rabeprazole on the PK of different formulations of PF-08049820.

    Time frame: Baseline up to Day 16 for Part A and up to Day 24 for optional Part B

  2. Area under the curve from time zero to extrapolated infinite time (AUCinf) if data permit

    Part A: Evaluate the relative bioavailability of 3 different formulations of PF-08049820. Optional Part B: Estimate the effect of rabeprazole on the PK of different formulations of PF-08049820.

    Time frame: Baseline up to Day 16 for Part A and up to Day 24 for optional Part B

  3. Maximum observed plasma concentration (Cmax)

    Part A: Evaluate the relative bioavailability of 3 different formulations of PF-08049820. Optional Part B: Estimate the effect of rabeprazole on the PK of different formulations of PF-08049820.

    Time frame: Baseline up to Day 16 for Part A and up to Day 24 for optional Part B

Secondary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    Part A and optional Part B

    Time frame: Baseline up to Day 48 for Part A and up to Day 56 for optional Part B

  2. Number of Participants With Serious Adverse Events (SAEs)

    Part A and optional Part B

    Time frame: Baseline up to Day 48 for Part A and up to Day 56 for optional Part B

  3. Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities

    Part A and optional Part B

    Time frame: Baseline up to Day 16 for Part A and up to Day 24 for optional Part B

  4. Number of Participants With Clinically Significant Change From Baseline in Vital Signs

    Part A and optional Part B

    Time frame: Baseline up to Day 16 for Part A and up to Day 24 for optional Part B

  5. Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Findings

    Part A and optional Part B

    Time frame: Baseline up to Day 16 for Part A and up to Day 24 for optional Part B

  6. Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)

    Part A only: Evaluate the food effect on the PK of different formulations of PF-08049820.

    Time frame: Baseline up to Day 16 for Part A

  7. Area under the curve from time zero to extrapolated infinite time (AUCinf) if data permit

    Part A only: Evaluate the food effect on the PK of different formulations of PF-08049820.

    Time frame: Baseline up to Day 16 for Part A

  8. Maximum observed plasma concentration (Cmax)

    Part A only: Evaluate the food effect on the PK of different formulations of PF-08049820.

    Time frame: Baseline up to Day 16 for Part A

07

Study locations

1 site
  • Pfizer Clinical Research Unit - New Haven
    New Haven, Connecticut 06511, United States
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from May 2026 to primary completion in Aug 2026, 2 months.

Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Aug 2026, on Oct 1, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2026
First posted
May 20, 2026
StartActual
May 13, 2026
Primary completionActual
Aug 7, 2026was Sep 2026
CompletionActual
Sep 1, 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 1, 2026
Primary completion
Sep 3, 2026→Aug 7, 2026 (actual)
Oct 1, 2026
Study completion
Sep 25, 2026→Sep 1, 2026 (actual)
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Recruiting→Completed
    Primary completion Sep 3, 2026→Aug 7, 2026 (now actual)
    Study completion Sep 25, 2026→Sep 1, 2026 (now actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07597928
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 20, 2026
Start date
May 13, 2026
Primary completion
Aug 7, 2026
Completion
Sep 1, 2026
Last update
Oct 1, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-08049820

Start the discussion